Welcome to Volume 10, Issue #1 (JANUARY 12, 2011) of Pharma Marketing News.
The drug industry brings legal heat to the issue of off-label drug promotion.
Boehringer-Ingelheim (BI) stands out in its attempt to stand out from the social(ist) cookie-cutter crowd of pharma FB pages. Shows what you can do with dedicated resources and creativity.
One survey says yes, pharma reps are important to physicians, another says not so much. Who are we to believe?
This is the last in a series of three articles highlighting points made by Kantar Health executives in a recent webinar titled, 'Getting It Right in the Emerging Markets: Identifying the opportunities and avoiding the pitfalls in conducting market research in new geographies.'
The whole web is now socialised..
Welcome to Volume 10, Issue #17 (10 NOVEMBER 2011) of Pharma Marketing News.
Pharmaceutical marketers have jumped on the mobile application bandwagon as more and more companies roll out health-related applications for smartphones and touchpads such as Apple's iPhone and iPad. But will the FDA regulate certain smartphone apps as medical devices? This article discusses the regulatory and other issues associated with pharma developed or sponsored health apps.
In a recent video titled 'What Gets PhRMA's Chairman Up Every Morning?', Chris Viehbacher, CEO of Sanofi, cited an impressive Potemkin number related to life expectancy and the pharma industry.
In a recent blog post, PhRMA said 'Without Promotion Research will be Useless.' To support its case, PhRMA cited 'an interesting opinion editorial' in the latest edition of the Annals of Emergency Medicine -- the medical journal of the American College of Emergency Physicians (ACEP). In the op-ed, entitled 'Limiting Gifts, Harming Patients,' Emory University economist Paul Rubin, Ph.D. expressed concern that ACEP policy regarding Gifts to Emergency Physicians from Industry 'could have the unfortunate effect of limiting the exchange of critical information between medicine makers and physicians about the benefits and risks of new medicines, how to use them properly and how best to diagnose the right candidates for particular treatments.'